23rd EVF Scientific Programme

Scientific Programme


08.00-08.30 ePoster Presentations in Lecture Hall

Chairs: Oscar Maleti (Italy)

08.30-10.30 Abstract Session 1: Venous Thromboembolism

(10 minute presentation, 10 minute discussion)

Chairs: Andrew Nicolaides (Cyprus), Erika Mendoza (Germany)

08.30-08.50     1.1 Interim One-year Safety And Effectiveness Outcomes Of A Mechanical Thrombectomy System For Treating Deep Vein Thrombosis: Results From The Real-world CLOUT Registry.

Gerd Grözinger*. University of Tübingen, Tübingen, Germany

08.50-09.10     1.2 Sulodexide and endothelial repair, a promising target for the acute approach of deep venous thrombosis management.

Erasto Aldrett*1; Erasto Aldrett2; Nora Enid Lecuona1; Marisol Aldrett Alvarez2. 1Grupo de Atención Vascular Integral, San Luis Potosí, Mexico; 2Grupo Dd Atencion Vascular Integral, San Luis Potosí, Mexico

09.10-09.30     1.3 Long-term results of tinzaparin for the treatment of superficial vein thrombosis of the lower limbs.

Chrysanthi Papageorgopoulou*; Konstantinos Nikolakopoulos; Spyros Papadoulas; Stavros Kakkos. University Hospital of Patras, Patras, Greece

09.30-09.50     1.4 Cancer-associated upregulation of thrombo-inflammatory markers, and endothelial marker among patients with pulmonary embolism.

Fakiha Siddiqui*1; Amir Darki2; Manuel Monreal3; Dilany Aliaga2; Debra Hoppensteadt2; Eduardo Ramacciotti2; Grigoris Gerotziafas4; Bulent Kantarcioglu2; Jawed Fareed2; Alfonso Tafur5.  1Loyola Univeristy Medical center, Maywood, USA; 2Loyola University Medical Center, Maywood, USA; 3Universidad Católica San Antonio de Murcia., Murcia, Spain; 4Univeristy of Paris, Paris, France; 5NorthShore University Health Systems, Skokie, USA

Submitted for the EVF Prize

09.50-10.10     1.5 Novel oral anticoagulants (NOACs) versus low molecular weight heparin (LMW) in prevention of venous thromboembolism (VTE) recurrence in cancer patients: a systematic review and meta-analysis.

Patricia Noreen Bueno*; William Bernard Ong; Frinz Moey Rubio; Lea Arceli Gonzales-Porciuncula. St. Luke’s Medical Center, Quezon City, Philippines

Submitted for the EVF Prize

10.10-10.30     1.6 Fit To Fly? A systematic review and meta-analysis of venous thromboembolism risk in surgical patients with recent air travel.

Jessie Shea*1; Avik Ghosh2; Benedict RH Turner2; Alun H Davies2; Sarah Onida2. 1London North West University Healthcare NHS Trust, London, UK; 2Imperial College London, London, UK

Submitted for the EVF Prize

10.30-11.00 Refreshments  |  Visit Exhibition
11.00-13.00 Abstract Session 2: Varicose Veins I

(10 minute presentation, 10 minute discussion)

Chairs: Alun Davies (UK), Tobias Hirsch (Germany)

11.00-11.20     2.1 5-year follow-up of a randomised controlled trial of endovenous laser ablation versus mechanochemical ablation for superficial venous incompetence (LAMA Trial).

Arthur JM Lim*; Abduraheem Mohamed; Louise Hitchman; Misha Sidapra; Bharadhwaj Ravindhran; Ross Lathan; George Smith; Ian Chetter; Daniel Carradice. Hull York Medical School, Hull, UK

Submitted for the EVF Prize

11.20-11.40     2.2 Saphenous vein mechano-chemical ablation by flebogrif catheter: mid – term (18 months). Results of the prospective multicentre trial (POLFLEB Study).

Tomasz Zubilewicz1; Tomasz Urbanek*2; Aleksandra Jaworucka-Kaczorowska3; Dariusz Janczak4; Piotr Terlecki1; Maciej Juśko5. 1Medical University Lublin, Lublin, Poland; 2Medical University of Silesia, Katowice, Poland; 3Jaworuccy Surgery and Gynecology Center, Gorzów Wielkopolski, Poland; 4Wrocław Medical Univeristy, Wrocław, Poland; 5Wroclaw Medical University, Wrocław, Poland

11.40-12.00     2.3 Comparison of radiofrequency ablation (RFITT) and glue chemical ablation (GCA) for incompetence of vena saphena magna et parva: A single center experience.

Maria Rosa Dassatti; Daniele Misuri; Stefan Haumer*. Krankenhaus Schlanders, Schlanders (Bz), Italy

12.00-12.20     2.4 Reflux origin of the insufficient small saphenous vein by duplex ultrasound determination and consequences for therapy.

Hans-Jürgen Veltman*1; Philipp Zollmann1; Maria Zollmann1; Christine Zollmann1; Ivonne Berger1; Anja Preller1; Erika Mendoza21Vein Office, Jena, Germany; 2Vein Office, Wunstorf, Germany

12.20-12.40     2.5 Variations of the saphenopopliteal junction: An ultrasonography study in young population and a meta-analysis.

Michaela Vesela*1; Michal Benes2; Gabriela Dostálová1; Ales Linhart1; David Kachlík2. 1General University Hospital in Prague, 1. LF Charles University, Prague, Czech Republic; 2. faculty of medicine, Charles University, Prague, Czech Republic

12.40-13.00     2.6 Results of a prospective observational study evaluating the effectiveness and tolerability of venoactive drugs combined with compression therapy in the treatment of venous disease CEAP Class C6: VAP-PRO-C6 study.

Vadim Yu Bogachev*1; Boris V Boldin1; Pavel Yu Turkin1; Alexandr Samenkov1; Olga Jenina1; Olga Linnik2. 1Pirogov Russian National Research Medical University, Moscow, Russia; 2Servier, Moscow, Russia

13.00-13.05 Special Announcement by the Chair Alun Davies.

VEIN: the Venous Ulcer Platform Study

13.05-14.00 Lunch
  Visit Exhibition
14.00-15.00 Industry Session 1
15.00-16.00 Didactic Session 1: Prevention and Management of Thrombosis

Chairs: Efthymios Avgerinos (Greece), Houman Jalaie (Germany),

15.00-15.15 Management of superficial vein thrombosis. Consequences from the INSIGHT Registry. Eberhard Rabe (Germany)
15.15-15.30 Deep dive into the Caprini score. Andrew Nicolaides (Cyprus)/Joe Caprini (USA)
15.30-15.45 Combined modalities in the prevention of VTE. Cochrane meta-analysis 2022. Stavros Kakkos (Greece)
15.45-16.00 Update on the management of deep vein thrombosis with anticoagulation. Rupert Bauersachs (Germany)
16.00-16.30 Refreshments  |  Visit Exhibition
16.30-17.30 Industry Session 2
17.30-18.30 Didactic Session 2: Chronic Venous and Lymphatic Disease and PTS

Chairs: Marzia Lugli (Italy), Rupert Bauersachs (Germany),

17.30-17.45 Cost-effectiveness of different international modalities and its new update. Armando Mansilha (Portugal)
17.45-18.00 CVD as an occupational disease. Tobias Hirsch (Germany)
18.00-18.15 Intervention of PTS: Who, when and how. Houman Jalaie (Germany)
18.15-18.30 Acute DVT intervention: Shifting from catheter thrombolytics to mechanical thrombectomy for prevention of PTS. Efthymios Avgerinos (Greece)
18.30-19.30 Welcome Reception



08.00-08.30 ePoster Presentations in Lecture Hall

Chairs: Dominik Heim (Switzerland)

08.30-10.30 Abstract Session 3: Varicose Veins II

 (10 minute presentation, 10 minute discussion)

Chairs: Tomasz Urbanek (Poland), Felizitas Pannier (Germany)

08.30-08.50  3.1 The epidemiology and risk factors of chronic venous disease and superficial vein reflux in a general population in the Netherlands — results from the Rotterdam study.

Eveline Scheerders*. Erasmus MC, Rotterdam, Netherlands

Submitted for the EVF Prize

08.50-09.10  3.2 Endovenous thermal ablation outcomes in relation to the diameter of incompetent great saphenous trunk.

Christos Karathanos*; Konstantinos Spanos; Konstantinos Batzalexis; Alexandros Barbatis; Konstantinos Tzimas- Dakis; Georgios Volakakis; Athanasios Chaidoulis; Georgios Kouvelos; Athanasios Giannoukas

Department of Vascular Surgery, University General Hospital of Larissa, University of Thessaly, Larissa, Greece

09.10-09.30  3.3 The safety of cyanoacrylate in varicose vein treatment: A review of type IV hypersensitivity and phlebitis-like reactions.

Eduardo Silva*; Helena Pereira; Vânia Constâncio-Oliveira; Celso Nunes; Leonor Baldaia; Miguel Silva; Luís Orelhas; Manuel Fonseca

Coimbra Hospital and University Centre, Coimbra, Portugal

Submitted for the EVF Prize

09.30-09.50  3.4 A novel screening tool for pelvic venous disorders.

Matthew Tan*1; Adam Gwozdz1; Tasneem Pope1; Alun Davies1; Sriram Narayanan2. 1Imperial College London, London, UK; 2The Venus Clinic Singapore and The Harley Street Heart & Vascular Centre, Singapore, Singapore

Submitted for the EVF Prize

09.50-10.10  3.5 Intraindividual comparison of 1470 nm and 1940 nm endovenous laser systems and biomatrix sclerosing foam.

Estephany Sifuentes Escobar*. Angioclinic Vein Centers, Berlin, Germany

Submitted for the EVF Prize

10.10-10.30  3.6 Results of numerical simulations of blood flow in the models of popliteal vein with elastic valves and with the leaflets of an increased stiffness.

Anas Rashid1; Syed Atif Iqrar2; Aiman Rashid3; Marian Simka*4

1University of Torino, Torino, Italy; 2Aston University, Birmingham, UK; 3University of Cagliari, Cagliari, Italy; 4University of Opole, Opole, Poland

10.30-11.00 Refreshments  |  Visit Exhibition
11.00-12.00 Industry Session 3
12.00-12.30 Abstract Session 4: CVI and Diabetes, Venous Malformations

(10 minute presentation, 5 minute discussion)

Chairs: Niels Baekgaard (Denmark), Dominic Muhlberger (Germany)

12.00-12.15  4.1 Identification and treatment of patients with concomitant chronic venous insufficiency and diabetes mellitus: A management algorithm using a modified Delph method.

Marie Josee van Tongerlo – van Rijn*1; Ahmet Kürşat Bozkurt2; Eliete Bouskela3; Giacomo Gastaldi4; Frederic Glauser5; Hermann Haller6; Juan Rosas-Saucedo7; Eberhard Rabe8; Armando Mansilha9.

1Erasmus Medical Cente, Rotterdam, Netherlands; 2Istanbul University-Cerrahpasa Medical Faculty, Istanbul, Turkey; 3State University of Rio de Janeiro, Rio de Janeiro, Brazil; 4Geneva University Hospitals, Geneva, Switzerland; 5Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland; 6Hannover Medical School, Hannover, Germany; 7Instituto de Diabetes de Celaya, AC. Celaya, Mexico; 8University of Bonn, Bonn, Germany; 9University of Porto and Hospital de S. João, Porto, Portugal

12.15-12.30  4.2 Endovascular laser treatment of marginal vein in patients with venous malformations.

Sergey Sapelkin*; Natalia Druzhinina; Alexander Kharazov; Irina Timina; Andrey Chupin, Niyazov N.N. The National Medical Research Center of Surgery n.a. A.V. Vishnevsky, Moscow, Russia

12.30-13.00 EVF Invited Lecture

Chair: Erika Mendoza (Germany)Introduction by Erika Mendoza

  Lipoedema-Syndrome – a paradigm shift. Tobias Bertsch (Germany)
13.00-14.00 Lunch
  Visit Exhibition
14.00-15.00 Prize winning papers from the Japanese Society of Phlebology, American Venous Form and American Vein and Lymphatic Society

(10 minute presentation, 5 minute discussion)

Chairs: Armando Mansilha (Portugal), Athanasios Giannoukas (Greece)

14.00-14.20  Pr1 Time-restricted salutary effects of blood flow restoration on venous thrombosis and vein wall injury in mouse and human subjects.

Wenzhu Li*1; Chase Kessinger2; Makoto Orii3; Hang Lee4; Lang Wang5; Ido Weinberg4; Michael Jaff4; Guy Reed6; Peter Libby7; Ahmed Tawakol4; Peter Henke8; Farouc Jaffer4

1Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai, China; 2Masonic Medical Research Institute, Utica, NY, USA; 3Iwate Medical University Hospital, Morioka, Japan; 4Massachusetts General Hospital, Boston, USA; 5Hubei Renmin Hospital, Wuhan, China; 6University of Arizona, Phoenix, USA; 7Brigham and Women’s Hospital, Boston, USA; 8Section of Vascular Surgery, Ann Arbor, USA

Winning abstract from Japanese Society of Phlebology

14.20-14.40  Pr2 The impact of venous outflow obstruction on venous return to the heart: preload, cardiac function and exercise tolerance before and after endovascular reconstruction.

R Morris, King’s College London, London, UK.

Winning abstract from American Venous Forum

15.00-16.00 Industry Session 4
16.00-16.30 Refreshments  |  Visit Exhibition
16.30-17.30  Joint EVF/AVF Session:

Chairs: (EVF), (Ruth Bush (USA) (AVF)

  Is all renal vein compression clinically relevant?
  AVF Leadership:
16.30-16.40 When renal vein compression is clinically relevant? Kathleen Ozsvath (USA)
16.40-16.50 When is renal vein compression clinical irrelevant? Julianne Stoughton (USA)
16.50-17.00 Discussion
  Documentation and measurements relevant to GSV
  EVF Leadership:
17.00-17.10 Standardised preoperative documentation as a basis for future evaluation of GSV treatment options in studies. Erika Mendoza (Germany)
17.10-17.20 Great saphenous vein diameter as factor for selection of thermal and non-thermal ablation. Athanasios Giannoukas (Greece)
17.20-17.30 Discussion
17.30-18.30 Annual General Meeting (members only)
20.00 Congress Dinner



08.00-08.30 ePoster Presentations in Lecture Hall

Chairs: Stavros Kakkos

08.30-10.30 Abstract Session 5: Varicose Veins III, The ABRE Study

(10 minute presentation, 10 minute discussion)

Chairs: Imre Bihari (Hungary), Eberhard Rabe (Germany)

08.30-08.50     5.1 Anatomy-adapted endovenous therapy of the saphenous-femoral junction. Tatjana Belyavskaya*. Angioclinic Vein Centers, Berlin, Germany
08.50-09.10    5.2 Contact time of sodium tetradecyl sulphate and venous endothelium for more than 5 seconds does not increase vein wall damage. Results of an ex-vivo vein study using immunohistochemistry.

Simon Muschamp; Melissa Kiely*; Simon Cheung; Danny Nguyen; Emma Moore; Anjali Bachetta; Mark Whiteley. The Whiteley Clinic, Guildford, UK

09.10-09.30    5.3 Glue embolization of perforator veins with direct puncture-technique. A moncentric experience.

Pier Giovanni Bianchi*; Luca Palombi; Fabio Martinelli. Fondazione Villa Salus, Ospedale Villa Salus, Mestre Venezia, Italy

09.30-09.50    5.4 The importance of breathing during exercise in chronic venous disease.

Rebeca Reachi-Lugo*. Hospital de Beneficencia Española, San Luis Potosi, Mexico

09.50-10.10 Invited Presentation. The ABRE Study. Three year results. Stephen Black, UK
10.10-10.30    5.5 Effects of micronized purified flavonoid fraction on inflammatory markers in patients undergoing minimally invasive treatment for varicose veins. A prospective cohort study.

Igor A Suchkov; Roman E. Kalinin; Aleksey A Kamaev; Nina D Mzhavanadze*

Ryazan State Medical University, Ryazan, Russia

10.30-11.00 Refreshments  |  Visit Exhibition
11.00-12.20 Abstract Session 6: Venous Wall

(10 minute presentation, 10 minute discussion)

Chairs: Marianne Vandendriessche (Belgium), Mark Malouf (Australia)

11.00-11.20  6.1 Comparative histological analysis in venous wall performed in patients with symptomatic chronic venous disease treated with a venotonic drug or without it.

Gerardo Estrada*1; Karla Garcia1; Amelia Estrada2; Irma Lopez3; Alejandro Loera1. 1Beneficencia Española de Tampico, Tampico, Mexico; 2Hospital General Carlos Canseco, Tampico, Mexico; 3Provascular Tampico, Tampico, Mexico

11.20-11.40  6.2 Action of HIFU (High Intensity Focused Ultrasound) on the venous wall: Histopathological analysis.

Paolo Casoni*1; Emanuele Nanni2; Matteo Pizzamiglio2; Luigi Serra3.

1Ippocrate Vein Academy, Parma, Italy; 2Ippocrate Vein Academy, Parma, Italy; 3Centro Emiliano Ricerche Biomediche, Parma, Italy


Enric Roche*1; Cristina Marqués2.
1Hospital Universitari Sagrat Cor, Barcelona, Spain; 2Clinica Vascular Barcelona, Barcelona, Spain

12.00-12.20  6.4 Ultrasound is a reliable and an accurate method to detect increased histological venous wall thickness among patients with chronic venous disease.

Sammi Zerrouk*1; Frederic Pamoukdjian2; Christophe Leboeuf3; Anne Janin3.

1Naborvein, St Avold, France; 2Université Paris Cité, Inserm, Bobigny, France; 3Université Paris Cité, Inserm, Paris, France

12.20-13.00 Industry Session 5
13.00-14.00 Didactic Session 3: Varicose Vein Surgery and Epidemiology Superficial Vein Disease

Chairs: Erika Mendoza, Albert Claude Benhamou

13.00-13.15 Surgery of superficial veins. A forgotten task in phlebology? Dominic Muhlberger (Germany)
13.15-13.30 How much Great Saphenous vein do we have to treat? Results of the SAPTAP Trial (isolated ambulatory phlebectomy with or saphenous thermal ablation) Renate van den Bos (Netherlands)
13.30-13.45 Bonn Vein Study. New results and implications of the revised CEAP classification. Felizitas Pannier (Germany)
13.45-14.00 Study on focal dilatations on GSV and its influence on the success of laser ablation. Imre Bihari (Hungary)
14.00 Presentation of 2024 Meeting  |  End of meeting

The views expressed in both oral and eposter presentations at the meeting are the views of the author(s) of the presentation. They are not necessarily the opinions and views of the European Venous Forum. Presentation at the meeting does not constitute an endorsement of the speaker’s views by the EVF. The presence of a company at the Exhibition does not constitute the European Venous Forum’s endorsement of a product or company. Congress delegates are expected to use their own diligence and medical judgement for clinical application.

Comments are closed.